Squarepoint
WGS icon

Squarepoint’s GeneDx Holdings WGS Stock Holding History

Squarepoint’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,100
Closed -$793K – 5062
2025
Q4 		$793K Sell
6,100
-3,200
-34% -$439K ﹤0.01% 2814
2025
Q3 		$1M Buy
9,300
+4,700
+102% +$512K ﹤0.01% 2691
2025
Q2 		$425K Buy
+4,600
New +$361K ﹤0.01% 3416

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's WGS Position: Q1 2026 in Review

Squarepoint increased its GeneDx Holdings (WGS) stake by 27% in Q1 2026, buying an estimated $469K and bringing the position to 24,180 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Squarepoint first reported a position in WGS in Q4 2021 and has held it in 13 quarters since. The position peaked at $8.39M in Q3 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Squarepoint held 24,180 shares of GeneDx Holdings worth $1.55M as of Q1 2026.
  • Squarepoint bought 5,144 GeneDx Holdings shares in Q1 2026, an estimated $469K.
  • GeneDx Holdings made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2399 holding.
  • Squarepoint first reported a position in GeneDx Holdings in Q4 2021 and has held it in 13 quarters since.
  • Squarepoint's GeneDx Holdings position peaked at $8.39M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.